We are live on ! Find out more
BIOC

Biocept, Inc.
BIOC

Delisted

BIOC was delisted on the 24th of October, 2023.

Back to rankings

11 hedge funds and large institutions have $96.4K invested in Biocept, Inc. in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

56% less funds holding

Funds holding: 25 → 11 (-14)

68% less capital invested

Capital invested by funds: $304K → $96.4K (-$208K)

82% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 17

Holders
11
Holders Change
-14
Holders Change %
-56%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
4
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$254K
2
BFM
Boothbay Fund Management
New York
+$133K
3
TRCT
Tower Research Capital (TRC)
New York
+$28.9K
4
JP Morgan Chase
JP Morgan Chase
New York
+$1.52K
5
Group One Trading
Group One Trading
Illinois
+$17

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$66K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$45.6K
3
BCM
Bridgeway Capital Management
Texas
-$32K
4
HF
HRT Financial
New York
-$18K
5
State Street
State Street
Massachusetts
-$13.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
– -$7 -1 Closed
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
– -$6 -1 -0.9%
1
2

BIOC Hedge Fund Activity: Q2 2023 in Review

11 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Biocept, Inc. (BIOC) for Q2 2023, worth a combined $96.4K — down 68% from $304K a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of BIOC and 3 opened new positions — a net loss of 14 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $254K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $66K sold.

  • 11 institutional investors held Biocept, Inc. (BIOC) as of Q2 2023, down from 25 in Q1 2023.
  • Funds reported $96.4K of Biocept, Inc. stock for Q2 2023, down 68% quarter-over-quarter.
  • 3 funds opened new Biocept, Inc. positions in Q2 2023 and 17 closed out, a net change of -14 holders.
  • The largest Biocept, Inc. buyer in Q2 2023 was Anson Funds Management, an estimated $254K added.
  • The largest Biocept, Inc. seller in Q2 2023 was Renaissance Technologies, an estimated $66K sold.

Based on aggregated 13F filings for Q2 2023.